Neuronetics, Inc. (STIM) - Form 8-K Summary
Business Context and Reporting Period
Neuronetics, Inc. filed a Current Report on Form 8-K on February 10, 2026. The filing announces the issuance of a press release containing selected preliminary unaudited financial results for the three and twelve months ended December 31, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol STIM.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs investors to the attached press release (Exhibit 99.1) for the preliminary results covering the three and twelve months ended December 31, 2025.
Guidance, Outlook, and Risks
The filing includes a comprehensive "Safe Harbor" statement regarding forward-looking information for fiscal year 2026, covering expectations for revenue, expenses, and growth. Management highlighted significant risks and uncertainties, including:
- The impact of a transaction with Greenbrook TMS Inc. on business relationships.
- The ability to achieve or sustain profitable operations given a history of losses.
- Reliance on the NeuroStar Advanced Therapy System for revenue generation.
- Reimbursement availability from third-party payors and physician/patient demand.
- Competitive developments and regulatory reviews for additional indications.
- The terms of the company's credit facility and ability to maintain positive cash flow.
- The successful rollout of the Better Me Provider Program.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the details and financial impact of the transaction with Greenbrook TMS Inc.
- Assess the status of the Better Me Provider Program rollout timeline.
- Confirm current cash balances and the terms of the existing credit facility to evaluate liquidity runway.
- Check for any updates on regulatory approvals for additional indications of the NeuroStar system.